MX2019012260A - Metodos de analisis mutacional y de metilacion del adn para vigilancia del cancer de vejiga. - Google Patents

Metodos de analisis mutacional y de metilacion del adn para vigilancia del cancer de vejiga.

Info

Publication number
MX2019012260A
MX2019012260A MX2019012260A MX2019012260A MX2019012260A MX 2019012260 A MX2019012260 A MX 2019012260A MX 2019012260 A MX2019012260 A MX 2019012260A MX 2019012260 A MX2019012260 A MX 2019012260A MX 2019012260 A MX2019012260 A MX 2019012260A
Authority
MX
Mexico
Prior art keywords
bladder cancer
dna methylation
analysis methods
mutational analysis
cancer surveillance
Prior art date
Application number
MX2019012260A
Other languages
English (en)
Inventor
Crager Michael
Knezevic Dejan
Lopatin Margarita
Febbo Phillip
Tsiatis Athanasios
N Silk Christopher
P Miller David
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of MX2019012260A publication Critical patent/MX2019012260A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente descripción se refiere a métodos para verificar pacientes con cáncer de vejiga y analizar muestras de pacientes para detectar la presencia de ADN metilado y opcionalmente mutaciones genéticas particulares. En algunas modalidades, los resultados del análisis son correlacionados con mediciones de resultados clínicos tales como el riesgo de recurrencia del cáncer de vejiga.
MX2019012260A 2017-05-18 2018-05-17 Metodos de analisis mutacional y de metilacion del adn para vigilancia del cancer de vejiga. MX2019012260A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508274P 2017-05-18 2017-05-18
PCT/US2018/033146 WO2018213550A1 (en) 2017-05-18 2018-05-17 Dna methylation and mutational analysis methods for bladder cancer surveillance

Publications (1)

Publication Number Publication Date
MX2019012260A true MX2019012260A (es) 2020-01-27

Family

ID=62528860

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012260A MX2019012260A (es) 2017-05-18 2018-05-17 Metodos de analisis mutacional y de metilacion del adn para vigilancia del cancer de vejiga.

Country Status (12)

Country Link
US (2) US11649506B2 (es)
EP (1) EP3625369B1 (es)
JP (1) JP2020519296A (es)
CN (1) CN110621788A (es)
AU (1) AU2018269030A1 (es)
BR (1) BR112019022360A2 (es)
CA (1) CA3057440A1 (es)
ES (1) ES2973607T3 (es)
IL (1) IL269707A (es)
MX (1) MX2019012260A (es)
SG (2) SG11201909113VA (es)
WO (1) WO2018213550A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114634982A (zh) * 2020-12-15 2022-06-17 广州市基准医疗有限责任公司 一种检测多核苷酸变异的方法
CN113621691A (zh) * 2021-09-27 2021-11-09 广东省妇幼保健院 基于一代测序技术直接检测KLF1基因启动子区CpG甲基化的方法和试剂盒
CN116013528B (zh) * 2023-01-10 2023-11-24 中山大学孙逸仙纪念医院 结合fish检测的膀胱癌术后复发风险预测方法、装置及介质
CN116987787A (zh) * 2023-06-09 2023-11-03 北京泛生子基因科技有限公司 检测膀胱癌是否复发的装置和计算机可读存储介质
CN116891899B (zh) * 2023-09-11 2024-02-02 北京橡鑫生物科技有限公司 一种基因标志物组合、试剂盒及检测方法
CN118006781A (zh) * 2024-02-27 2024-05-10 广州中鑫基因医学科技有限公司 用于检测尿路上皮癌的标志物、引物组、高敏感性和高特异性的试剂盒及检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2409767B1 (en) 2005-06-23 2018-08-08 Biocartis NV Modular cartridge, system and method for automated medical diagnosis
CA2759312C (en) * 2009-04-20 2019-12-31 Erasmus University Medical Center Rotterdam Method of diagnosing bladder cancer
EP2966181B1 (en) * 2009-06-26 2018-02-14 Epigenomics AG Methods and nucleic acids for analysis of bladder carcinoma
CN103417983A (zh) * 2012-05-18 2013-12-04 北京大学 新的凋亡相关分子tmem106a及其用途
WO2014085666A1 (en) 2012-11-27 2014-06-05 Board Of Regents, The University Of Texas System Methods of characterizing and treating molecular subset of muscle-invasive bladder cancer
EP2994545B1 (en) * 2013-05-10 2019-03-20 University Of Southern California Dna methylation biomarkers for bladder cancer
WO2015116837A1 (en) 2014-01-30 2015-08-06 The Regents Of The University Of California Methylation haplotyping for non-invasive diagnosis (monod)
GB201511152D0 (en) * 2015-06-24 2015-08-05 Ucl Business Plc Method of diagnosing bladder cancer

Also Published As

Publication number Publication date
WO2018213550A1 (en) 2018-11-22
SG10201912359XA (en) 2020-02-27
EP3625369A1 (en) 2020-03-25
CN110621788A (zh) 2019-12-27
IL269707A (en) 2019-11-28
ES2973607T3 (es) 2024-06-20
CA3057440A1 (en) 2018-11-22
US11649506B2 (en) 2023-05-16
US20200165686A1 (en) 2020-05-28
AU2018269030A1 (en) 2019-10-17
BR112019022360A2 (pt) 2020-05-19
US20230374604A1 (en) 2023-11-23
EP3625369B1 (en) 2024-02-14
SG11201909113VA (en) 2019-10-30
JP2020519296A (ja) 2020-07-02

Similar Documents

Publication Publication Date Title
MX2019012260A (es) Metodos de analisis mutacional y de metilacion del adn para vigilancia del cancer de vejiga.
HK1254531A1 (zh) 用於癌症檢測和監測腫瘤組織樣品的制備和分析方法
MX2017015260A (es) Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer.
WO2016138105A3 (en) Assays to determine dna methylation and dna methylation markers of cancer
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
WO2018183817A3 (en) Tumor burden as measured by cell free dna
MX2016012697A (es) Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
WO2014145751A3 (en) Targeted therapies for cancer
EA201691682A1 (ru) Способы анализирования редких циркулирующих в крови клеток
EP3990659A4 (en) DETECTION AND TREATMENT OF RESIDUAL DISEASE USING CIRCULATING TUMOR DNA ANALYSIS
WO2016034715A3 (fr) Methode de prediction de l'evolution clinique du cancer colorectal
GB2523211A8 (en) MCT protein inhibitor-related prognostic and therapeutic methods
WO2016201365A3 (en) Methods for treating cancers
EP3371211A4 (en) METHOD FOR THE TREATMENT OF TUMORS AND CANCER AND IDENTIFICATION OF CANDIDATE PATIENTS FOR SUCH TREATMENT
WO2013188823A3 (en) Cancer prognostic assays
WO2017053763A3 (en) ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC)
BR102015015096A2 (pt) método de detecção in vitro de câncer de tireoide em um paciente, método in vitro de diferenciação entre câncer de tireoide e tecido de tireoide normal ou de lesões benignas de tireoide, uso de um conjunto de genes, método de obtenção de dados para direcionamento do tratamento do cancer de tireoide, kit laboratorial e dispositivo para classificar uma amostra biológica de glândula tireoide como maligna ou benigna
WO2016018524A8 (en) E2f4 signature for use in diagnosing and treating breast and bladder cancer
Arastefar et al. The prevalence of CMV and EBV among the patients with the colorectal cancer; a molecular approach
WO2015193738A3 (en) Methods and biomarkers for analysis of colorectal cancer
WO2015021263A3 (en) Methylation biomarkers for colorectal cancer
UA99752U (uk) Спосіб прогнозування гематологічної токсичності хіміотерапії у хворих на рак грудної залози
UA96044U (uk) Спосіб прогнозування зрощення перелому
UA96046U (uk) Спосіб прогнозування зрощення перелому
UA96045U (uk) Спосіб прогнозування зрощення перелому